Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.49 |
| ▸ | MTOR | P42345 | 11/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.49 |
| ▸ | NT5E | P21589 | 4/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556426 | 0.94 | PIK3CA (0.52) | PIK3CAMTORPIK3CGNT5EADORA3 | |
| SCHEMBL336144 | 0.86 | PIK3CA (0.46) | PIK3CAMTORPIK3CGNT5E | |
| SCHEMBL25237682 | 0.83 | NT5E (0.52) | PIK3CAMTORPIK3CGNT5E | |
| SCHEMBL774618 | 0.82 | PNP (0.46) | ADORA3PNP | |
| SCHEMBL4446284 | 0.82 | PIK3CA (0.49) | PIK3CAMTORPIK3CGNT5E | |
| SCHEMBL18114702 | 0.79 | NT5E (0.47) | PIK3CAMTORNT5E | |
| Trifluoroacetic Acid SCHEMBL4448005 | 0.79 | PIK3CA (0.55) | PIK3CAMTORPIK3CGNT5EADORA3 | |
| SCHEMBL27781912 | 0.79 | NT5E (0.47) | PIK3CAMTORPIK3CGNT5E | |
| SCHEMBL4440236 | 0.77 | PIK3CA (0.69) | PIK3CAMTORPIK3CG | |
| SCHEMBL16473605 | 0.77 | PIK3CA (0.55) | PIK3CAMTORPIK3CGNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336132-B1 | MORPHOLINOPURINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PIK3CA 22/4885MTOR 1/4885PIK3CG 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.